Considering enrolment in clinical trials for patients with amyloidosis

Considering enrolment in clinical trials for patients with amyloidosis

The potential role of machine learning in amyloidosis

The potential role of machine learning in amyloidosis

Unmet needs that remain in stage 3B and R/R amyloidosis

Unmet needs that remain in stage 3B and R/R amyloidosis

HRQoL, diagnosis and treatment experiences of patients with AL amyloidosis: a survey by MPE

HRQoL, diagnosis and treatment experiences of patients with AL amyloidosis: a survey by MPE

Detection of circulating TTR aggregates: a potential novel biomarker for ATTR amyloidosis

Detection of circulating TTR aggregates: a potential novel biomarker for ATTR amyloidosis

Selecting therapeutics for treating early relapses in multiple myeloma

Selecting therapeutics for treating early relapses in multiple myeloma

Patient-reported outcomes from the GRIFFIN trial: D-RVd versus RVd in multiple myeloma

Patient-reported outcomes from the GRIFFIN trial: D-RVd versus RVd in multiple myeloma

Novel agents in development for multiple myeloma: CELMoDs, antibody-drug conjugates, and peptides

Novel agents in development for multiple myeloma: CELMoDs, antibody-drug conjugates, and peptides

Ide-cel versus cilta-cel in multiple myeloma: a collaborative decision between patient and doctor

Ide-cel versus cilta-cel in multiple myeloma: a collaborative decision between patient and doctor

Choosing between ide-cel and cilta-cel for the treatment of R/R multiple myeloma

Choosing between ide-cel and cilta-cel for the treatment of R/R multiple myeloma

Unmet treatment needs in subgroups of patients with multiple myeloma

Unmet treatment needs in subgroups of patients with multiple myeloma

Comparison of the Simoa and MSD R-PLEX assays to assess serum NfL levels in ATTR amyloidosis

Comparison of the Simoa and MSD R-PLEX assays to assess serum NfL levels in ATTR amyloidosis

Prophylactic tocilizumab to mitigate CRS: results from a small cohort in the MajesTEC-1 trial

Prophylactic tocilizumab to mitigate CRS: results from a small cohort in the MajesTEC-1 trial

Diagnostic utility of left atrial and right ventricular strain analyses in AL amyloidosis

Diagnostic utility of left atrial and right ventricular strain analyses in AL amyloidosis

Combining pembrolizumab with BCR inhibitors for Richter's transformation

Combining pembrolizumab with BCR inhibitors for Richter's transformation

Investigating the impact of pacritinib on survival in patients with MF and severe thrombocytopenia

Investigating the impact of pacritinib on survival in patients with MF and severe thrombocytopenia

Emavusertib in combination with azacitidine and venetoclax in patients with AML

Emavusertib in combination with azacitidine and venetoclax in patients with AML

The combination of FDG PET plus whole-body MRI for diagnosing multiple myeloma

The combination of FDG PET plus whole-body MRI for diagnosing multiple myeloma

How will novel agents be sequenced for patients with multiple myeloma?

How will novel agents be sequenced for patients with multiple myeloma?

Cilta-cel vs standard of care in functional high-risk myeloma: findings from CARTITUDE-4

Cilta-cel vs standard of care in functional high-risk myeloma: findings from CARTITUDE-4

Machine learning-based clustering to improve risk stratification in newly diagnosed AL amyloidosis

Machine learning-based clustering to improve risk stratification in newly diagnosed AL amyloidosis

The value of close collaboration between cardiologists, hematologists & other MDTs in amyloidosis

The value of close collaboration between cardiologists, hematologists & other MDTs in amyloidosis

Treating mantle cell lymphoma: past approaches and future perspectives

Treating mantle cell lymphoma: past approaches and future perspectives

Daratumumab-based frontline therapy in AL amyloidosis: real-world Mayo Clinic experience

Daratumumab-based frontline therapy in AL amyloidosis: real-world Mayo Clinic experience

Updated safety & efficacy data from MANIFEST-2: pelabresib plus ruxolitinib for myelofibrosis

Updated safety & efficacy data from MANIFEST-2: pelabresib plus ruxolitinib for myelofibrosis

An overview of trials in progress in AL amyloidosis: highlights from ISA 2024

An overview of trials in progress in AL amyloidosis: highlights from ISA 2024

Advances in the diagnosis of AL amyloidosis: AmyLite diagnostic assay

Advances in the diagnosis of AL amyloidosis: AmyLite diagnostic assay

Findings from DREAMM-7 establish belantamab mafodotin as a new SoC for R/R multiple myeloma

Findings from DREAMM-7 establish belantamab mafodotin as a new SoC for R/R multiple myeloma

The impact of renal impairment on clinical outcomes with mezigdomide plus dex in R/R myeloma

The impact of renal impairment on clinical outcomes with mezigdomide plus dex in R/R myeloma

CELESTIAL-TNCLL: ongoing Phase III study of sonrotoclax + zanubrutinib vs ven + obi for TN CLL

CELESTIAL-TNCLL: ongoing Phase III study of sonrotoclax + zanubrutinib vs ven + obi for TN CLL